Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in Japanese healthy adults: A Phase I study

V116 is an investigational 21-valent pneumococcal conjugate vaccine (PCV) to address the burden of residual adult pneumococcal disease after the introduction of pediatric PCVs into national immunization programs (NIPs) and includes serotypes highly prevalent in adult invasive pneumococcal disease (I...

Descripción completa

Detalles Bibliográficos
Autores principales: Haranaka, Miwa, Yono, Makoto, Kishino, Hiroyuki, Igarashi, Rie, Oshima, Nobuyuki, Sawata, Miyuki, Platt, Heather Loryn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Pneumococcal
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316726/
https://www.ncbi.nlm.nih.gov/pubmed/37389808
http://dx.doi.org/10.1080/21645515.2023.2228162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316726/
https://www.ncbi.nlm.nih.gov/pubmed/37389808
http://dx.doi.org/10.1080/21645515.2023.2228162

Ejemplares similares